Get in touch about GlobalData Company reports
Contact the team or request a demo to find out how our data can drive your business forward
Trevena Inc (Trevena) is a biopharmaceutical company that develops and commercializes innovative medicines for central nervous system (CNS) disorders. The company's pipeline products OLINVYK (Oliceridine injection), TRV045, TRV734 and TRV250. Its OLINVYK (oliceridine) injection, is a G protein-biased mu-opioid receptor (MOR) ligand for managing moderate-to-severe acute pain. Its TRV045 is an oral drug used for the treatment of acute and chronic neuropathic pain secondary to diabetic peripheral neuropathy. Trevena’s TRV734 is also an oral drug that is used in medication-assisted therapy for the treatment of opioid use disorder and TRV250 is an oral delta opioid-biased ligand for the treatment of acute migraine. Trevena is headquartered in Atlanta, Georgia, the US.
Headquarters
United States of America
Address
Suite 502, 2870 Peachtree Road, Atlanta, Georgia, 30305
Website
www.trevena.com
Telephone
1 610 3548840
No of Employees
23
Industry
Pharmaceuticals and Healthcare
Ticker Symbol & Exchange
TRVN (OTC)
Revenue (2023)
$3.1M
847.6%
(2023 vs 2022)
EPS
XYZ
Net Income (2023)
XYZ
24.9%
(2023 vs 2022)
Net Profit Margin (2023)
XYZ
0.0%
(2023 vs 2022)
* As of and is in US$
Products and Services
| Products | Brands |
|---|---|
| Pipeline | OLINVYK |
| TRV250: Acute Migraine | |
| TRV734: Opioid Use Disorder | |
| XYZ | |
| XYZ | |
| XYZ |
Competitor Comparison
| Key Parameters | Trevena Inc | Keenova Therapeutics plc | Heron Therapeutics Inc | Cumberland Pharmaceuticals Inc | Baudax Bio Inc |
|---|---|---|---|---|---|
| Headquarters | United States of America | Ireland | United States of America | United States of America | United States of America |
| City | Atlanta | Blanchardstown | Cary | Nashville | Malvern |
| State/Province | Georgia | Dublin | North Carolina | Tennessee | Pennsylvania |
| No. of Employees | 23 | 2,800 | 122 | 93 | 9 |
| Entity Type | Public | Private | Public | Public | Public |
Key Financial Charts
Sales Growth
Net Income Growth
Executives
| Name | Position | Board | Since | Age |
|---|---|---|---|---|
| Carrie L. Bourdow | Chief Executive Officer - Acting | Senior Management | - | - |
| Non Dignissim Eros | Proin vel | Convallis | 2026 | XY |
| Non Dignissim Eros | Proin vel | Convallis | 2026 | XY |
| Non Dignissim Eros | Proin vel | Convallis | 2026 | XY |
Still looking?
Have you found what you were looking for? From start-ups to market leaders, uncover what they do and how they do it.
Explorer
Access more premium companies when you subscribe to Explorer